Meniere's Disease Drug Market - Industry Trendst

zac shipping
zac shipping 1/27/2021 5:14:14 AM

Meniere's Disease Drug Market - Industry Trends and Forecast to 2026 with key players like Otonomy Inc., WellSpring Pharmaceutical Corporation, Sound Pharmaceutical, Jubilant Cadista, Auris Medical, Pfizer Inc, Sun Pharmaceutical Industries Ltd

Meniere's Disease Drug Market  ­By Type ( Classic, Vestibular and Bilateral), Mechanism of Action (Antihistamines, Benzodiazepines, Antinausea, Diuretics, Antibiotics, Steroids and Others), Drugs (Meclizine, Diazepam, Prochlorperazine, Hydrochlorothiazide, Gentamicin, Dexamethasone and Others), Devices (Hearing Aid, Meniett device), Treatment (Medications, Therapy or Hearing Aids, Surgery), Route of Administration (Oral, Intravenous, Intratympanic and Others), Distribution Channel (Online Pharmacy, Direct Tenders, Retailers and Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Geography (North America, Europe, South America, Asia-Pacific, Middle East and Africa) - Industry Trends and Forecast to 2026

Market Analysis: Global Meniere's Disease Drug Market  

Global Meniere's disease drug Market is expected to grow at a substantial CAGR in the forecast period of 2021-2026. The report contains data of the base year 2018 and historic year 2017. This rise in market value can be attributed to the high prevalence of hearing disorders and the lack of any approved treatment options. Rising investment in the research & development of treatments for Meniere’s disease is expected to drive the market.

Download full sample report of Meniere's Disease Drug Market   @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-menieres-disease-drug-market

Market Definition: Global Meniere's Disease Drug Market  

Meniere’s disease is a disorder of inner-ear that typically affects one ear, inner ear is responsible for hearing and balance. This condition can cause vertigo, ringing in the ear (tinnitus), feeling of pressure in the ear, specific type of dizziness in which patient feel like spinning, hearing loss that comes and goes. This is a chronic condition and can lead to permanent hearing loss but treatments and lifestyle changes can help to control the symptoms.

According to the report of National Institute on Deafness and Other Communication Disorders of America, the prevalence of Meniere’s disease is high in America and around 615,000 Americans are suffering from Meniere’s disease and the number of patients increasing every year. Massachusetts Eye and Ear (An international center for treatment and research and a teaching hospital of Harvard Medical School) reported that approximately 60,000 new cases of Meniere’s disease are diagnosed annually.

Market Drivers

High prevalence of Meniere’s disease is driving the market growth

Increasing awareness of this disorder is another important factor for the market growth

Rising investment in the research & development for the treatments for this disease is expected to drive the market growth

Government initiative to increase awareness is elevating the market growth

Market Restraints

Lack of any approved drug or treatment option is restricting the market growth

Low healthcare expenditure in developing regions also acts as a market restraint

High cost of treatment for this disease can also hamper the market growth

Segmentation: Global Meniere's Disease Drug Market  

By Type

·       Classic

·       Vestibular

·       Bilateral

By Mechanism of Action

·       Anti-Histamines

·       Benzodiazepines

·       Antinausea

·       Diuretics

·       Antibiotics

·       Steroids

·       Others

By Drugs Type

·       Meclizine

·       Diazepam

·       Prochlorperazine

·       Hydrochlorothiazide

·       Gentamicin

·       Dexamethasone

·       Others

By Devices type

·       Hearing Aid

·       Meniett device

By Treatment Type

·       Medications

·       Therapy or Hearing Aids

·       Surgery

By Route of Administration

·       Oral

·       Intravenous

·       Intratympanic

·       Others

By Distribution Channel

·       Online Pharmacy

·       Direct Tenders

·       Retailers

·       Others

By End-Users

·       Hospitals

·       Homecare

·       Specialty Clinics

·       Others

By Geography

·       North America

·       U.S.

·       Canada

·       Mexico

·       Europe

·       Germany

·       Italy

·       U.K.

·       France

·       Spain

·       Netherlands

·       Belgium

·       Switzerland

·       Turkey

·       Russia

·       Rest of Europe

·       Asia-Pacific

·       Japan

·       China

·       India

·       South Korea

·       Australia

·       Singapore

·       Malaysia

·       Thailand

·       Indonesia

·       Philippines

·       Rest of Asia Pacific

·       South America

·       Brazil

·       Rest of South America

·       Middle East & Africa

·       South Africa

·       Rest of Middle East & Africa

Key Developments in the Market

In June 2019, Otonomy Inc. is developing Otividex drug for the treatment of Meniere’s disease which is under Phase 3 clinical trial, in November 2017 Otonomy Inc announced that the AVERTS-2 trial, conducted in Europe, achieved its primary endpoint (p value = 0.029) and Otividex demonstrated clinically significant treatment benefit for patients

In May 2018, FDA approved IDE study for the treatment of Meniere’s disease and intractable vertigo. In this study simultaneously labyrinthectomy and cochlear implantation can be done in unilateral Meniere's disease  which further assists  in determining speech perception, localization and quality of life outcomes

Competitive Analysis:

Global Meniere’s disease drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Meniere’s disease drug market for Global Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Market Players:

The key market players in the global Meniere’s disease drug market are Abbott, Otonomy Inc., WellSpring Pharmaceutical Corporation, Sound Pharmaceutical, Jubilant Cadista, Auris Medical, Pfizer Inc, Sun Pharmaceutical Industries Ltd, Novartis AG, Abbott, Bayer AG, GlaxoSmithKline plc, Amneal Pharmaceuticals LLC., LUPIN, Sanofi, Solvay, XOMA and others.

 

Get full details of TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-menieres-disease-drug-market  

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-menieres-disease-drug-market  

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:

Data Bridge Market Research 

Tel: +1-888-387-2818

Email: Sopan.gedam@databridgemarketresearch.com

Browse Related Reports @

Monkeypox Market 

Acitretin Market 

 

zac shipping
Written by

zac shipping

Post a comment